Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00864396 · ClinicalTrials.gov registry record · Phase 1
Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux
A Phase 1 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT00864396 is a Phase 1 study that has completed, run by University of California, Davis. The registered enrollment target is 59 participants.
The verdict
NCT00864396, a Phase 1 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether treatment with twice-daily Lansoprazole 30mg (Prevacid 30mg) and behavioral modifications for reflux is superior to treatment with behavioral modifications for reflux alone in the treatment of laryngopharyngeal reflux (LPR).
Interventions
- DRUG Prevacid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2005-07 |
| Est. Completion | 2008-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00864396
The ClinicalTrials.gov registry entry for NCT00864396 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Prevacid is the first listed.
NCT00864396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00864396 about?
NCT00864396 is a clinical study titled "Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux". The purpose of this study is to determine whether treatment with twice-daily Lansoprazole 30mg (Prevacid 30mg) and behavioral modifications for reflux is superior to treatment with behavioral modifications for reflux alone in the treatment of laryngopharyngeal reflux (LPR).
What is the current status of trial NCT00864396?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2005-07. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00864396?
The interventions under investigation include: Prevacid (DRUG).
Who is sponsoring clinical trial NCT00864396?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.